Business Context and Reporting Period
Company: Cara Therapeutics, Inc. (Note: Request metadata listed "Tvardi Therapeutics," but the filing identifies the registrant as Cara Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2019
Reporting Period: Second quarter ended June 30, 2019
Context: The filing serves to announce the issuance of a press release regarding the Company's financial results for the second quarter of 2019. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes regarding financial performance or operations are detailed in the provided text. The document solely confirms the announcement of Q2 2019 results via a press release.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the actual financial figures (Revenue, Net Loss, Cash Position) by reviewing Exhibit 99.1 (Press Release dated August 7, 2019), as they are not present in the 8-K cover text.
- Confirm the company name is Cara Therapeutics, Inc. (Ticker: CARA), noting a discrepancy with the "Tvardi Therapeutics" name in the request metadata.
- Check for any subsequent filings or updates regarding the Q2 2019 results if the press release is not immediately accessible.
- Review the Company's status as an Emerging Growth Company (indicated as checked in the filing) for potential differences in financial reporting standards.